Hypermethylation of FRZB has also been shown to decrease its expression in MDS stroma, leading to activation of WNT/β-catenin signalling in CD34+ cells from advanced cases of MDS and is associated with adverse prognosis (Figure 2) [162]. This evidence concerns the gene CD34 and myelodysplastic syndrome.